Bayer to unveil late-breaking data from Phase III OASIS 1 and 2 for elinzanetant in the treatment of vasomotor symptoms associated with menopause
Business Wire
BERLIN--(BUSINESS WIRE)--Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, evaluating the..